No Data
Insider decrases its stake in J Frontier(2934.JP) to 6.55%
On Nov 7, 明治安田アセットマネジメント株式会社 submitted the Change Report to Ministry of Finance. The report shows that 明治安田アセットマネジメント株式会社 decreased their holdings in $J Frontier(2934.JP)$, with their joint
Stocks that moved on the previous day part 2: Tokyo Electron Ltd. unsponsored adr, SoftBank Group, Birdman, etc.
Stock Name 4-day closing price ⇒ Previous day's change Advantest＜6857＞ 6129 -514 NVIDIA Inc. is down nearly 10%. Tokyo Electron＜8035＞ 22995 -2150 Also selling in the main brand of the semiconductor-related downturn. Hokkaido Electric Power＜9509＞ 1014 -66.5 The decline in semiconductor-related stocks is also affecting the datacenter business. SoftBank Group＜9984＞ 7781 -652 Following the decline of the NASDAQ index. First
Emerging markets stock digest: Flutter plunged sharply, Carnavio continued to soar significantly.
Decline. After the close of trading on the 2nd, it was announced that the financial estimates for the full year ending in May 2024 have been withdrawn and are undecided, which has led to selling pressure.
Soft tone, lacking clues and difficult to determine direction.
[Emerging Markets Individual Stock Strategy] Today, emerging markets are expected to see a weak development. The U.S. stock market was closed on the 2nd for Labor Day. In European major markets, the UK's FTSETM100 fell by 0.15%, Germany's DAX rose by 0.13%, and France's CAC40 rose by 0.20%. It seems that selling will dominate the market in today's emerging markets. With the U.S. market closed yesterday and European major markets showing mixed movements with minor fluctuations, which makes it difficult to provide clues for the Tokyo market, the market is anticipating a rate cut by the U.S.
Rakuauria Pharmaceuticals, Renascience, and others
<2586> The number of shares to be issued from the large exercise of the 15th subscription rights (with exercise price adjustment clause) is 3.37 million shares. <2934> Application for approval regarding the extension of the submission deadline for the J Frontier securities report. <4572> The start of the dose expansion part of the phase 1b trial of AS-1763 BTK inhibitor drug by Carna Bio. <4579> Obtained sales approval for Tegoprazan, a Rakulia drug for gastric acid secretion inhibition, in Columbia. <4888> Stella Pharma.
J Frontier: Notice regarding the withdrawal of the full-year consolidated earnings forecast for the fiscal year ending May 2024
No Data
No Data